申聯生物(688098.SH):與中國農業科學院蘭州獸醫研究所簽訂多聯多價疫苗項目合作開發合同
格隆匯7月31日丨申聯生物(688098.SH)公佈,公司與中國農業科學院蘭州獸醫研究所(簡稱“蘭研所”)等單位簽訂了《豬口蹄疫O型/A型、豬瘟、偽狂犬病三聯疫苗技術開發(合作)合同》及《牛口蹄疫O型/A型、病毒性腹瀉/黏膜病、傳染性鼻氣管炎三聯疫苗技術開發(合作)合同》,共同開發豬用口蹄疫等三種疫病多聯多價疫苗及牛用口蹄疫等三種疫病多聯多價疫苗,合作各方按照協議約定任務和分工,各自承擔相關費用,合作研發項目產生的技術成果及知識產權歸公司及蘭研所兩方共同享有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.